Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Abstract: The present invention relates to novel dispersants based on reaction products of two and one moles respectively of the branched ester alcohol or alkokylated ester alcohol with maleic anhydride that has been subjected to a further sulfonation reaction. The compounds are useful as dispersing and wetting agents. The invention further relates to the use of the dispersants of the invention to produce stable aqueous dispersions of high performance thermoplastic polymers.

Abstract: A process for the manufacture of dialkyl phosphites is disclosed. In detail, dialkyl phosphites are prepared starting from P4O6, or partially hydrated species thereof cumulatively P—O, by reacting specific molar ratios of alcohol and P—O, containing from 1 to 6 P—O—P bonds in the molecule, in the presence of trialkylphospite (TAP) to thus yield high purity and high yield of dialkyl phosphites. The P—O reactant is preferably represented by liquid P4O6.

Abstract: Hydrophilic, biocidal coating compositions and methods to make and use the compositions are disclosed. The coatings include compounds with quaternary amine polyethylene glycol groups and polyaminoalkyl biguanide groups as substituents. The compounds when incorporated in paints provide hydrophilic, self-cleaning and biocidal property to the coating.

Abstract: The invention relates to a method for producing mono-carboxyfunctionalized dialkylphosphinic acids and esters and salts thereof, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) to yield an alkylphosphonic acid, salt or ester (H) thereof in the presence of a catalyst A, b) the thus obtained alkylphosphonic acid, salt or ester (II) thereof is reacted with compounds of formula (V) to yield mono-functionalized dialkylphosphinic acid derivatives (VI) in the presence of a catalyst B, and c) the thus obtained mono-functionalized dialkylphosphinic acid derivatives (VI) are reacted to yield a mono-carboxyfunctionalized diakylphosphinic acid derivative (III) in the presence of a catalyst C, wherein R1, R2, R3, R4, R5, R6, R7 are the same or different and stand independently of each other, among other things, for H, C1-C18 alkyl, C6-C18 aryl, C6-C18 aralkyl, C6-C18 alkylaryl and X and Y are the same or different and stand independently of each for H, C1-C18 alkyl, C6-C18 aryl, C6-C18 a

Abstract: Addition compounds of a) alkylphosphonous acid derivatives of the formula A-P(?O)(OX)—H (I) and b) diester-forming olefins of formula (II) Methods for the production of the addition compounds and the use thereof are also disclosed.

Abstract: A device including an electrode, the electrode having a surface; a molecule bound to the surface of the electrode through a binding group; an organic electronic material in electrical contact with the electrode, wherein the molecule comprises at least one fluorinated aryl group, wherein the electrode contains a transparent conductive metal oxide, a carbon nanotube, or graphene.

Abstract: The object of the present invention is the use of phosphonium salts in coupling reactions, and a method for their preparation.

Abstract: There is provided to a method for efficiently producing phosphonic acid metal salt fine particles with an average particle diameter of 0.5 ?m or less with high efficiency. A method for producing phosphonic acid metal salt fine particles, comprising: a) causing a reaction of a phosphonic acid compound of Formula (I): (where R1 and R2 are each independently a hydrogen atom, an alkyl group having 1 to 10 carbon atoms, or an alkoxycarbonyl group having 1 to 10 carbon atoms) with a base in an aqueous medium to adjust a pH range of the reaction system to be neutral to basic; b) causing a reaction of the product obtained in a) with a metal salt to precipitate a phosphonic acid metal salt from the aqueous medium; c) removing water from the phosphonic acid metal salt precipitated in b); and d) heating and drying the phosphonic acid metal salt from which water is removed in c).

Abstract: Provided are a drug, a cosmetic, etc. for promoting production of ceramide. Provided is a ceramide production promoter including a compound represented by the formula (1) or salts thereof as an active ingredient (in the formula, R1 represents a phosphono group or a hydrogen atom, R2 represents an alkyl group having 8 to 24 carbon atoms or an acyl group having 8 to 24 carbon atoms, and R3 represents an alkyl group having 1 to 24 carbon atoms when R1 represents a phosphono group or represents a phosphono group when R1 represents a hydrogen atom, or a salt thereof as an active ingredient.

Abstract: Disclosed are phosphinic acid compounds of formula I, II or III where R1 and R1? are for instance straight or branched C1-C50alkyl, R2 is for instance straight or branched C22-C50alkyl, R3 and R3? are for instance straight or branched C1-C50alkyl, R4 is for instance straight or branched C1-C50alkylene and m is from 2 to 100. Also disclosed are polyester compositions comprising the compounds of formula I, II and III.

Abstract: HPV inhibitors with formula (I) where G1 represents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, G2 represents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethyl, G represents a bond or a hydrocarbonated chain possibly substituted by one or two alkyls, W represents an oxygen or sulphur, R1 and R2 each represent a group chosen from among hydrogen, halogen, hydroxyl, thio, alkoxy, halogenoalkoxy, alkylthio, halogenoalkylthio, amino, monoalkylamino, dialkylamino, cycloalkyl, alkyl or halogenoalkyl, R3 represents an acid or a prodrug radical of the acid function or a bioisostere of the acid function, A represents an aryl, cycloalkyl, cycloalkenyl or a heterocycle, each possibly substituted, and B represents an aryl or a heterocycle with 6 chains, each possibly substituted, and pharmaceutically acceptable salts.

Abstract: A process for the manufacture of dialkyl phosphites is disclosed. In detail, dialkyl phosphites are prepared starting from P4O6, or partially hydrated species thereof cumulatively P—O, by reacting specific molar ratios of alcohol and P—O, containing from 1 to 6 P—O—P bonds in the molecule, in the presence of trialkylphospite (TAP) to thus yield high purity and high yield of dialkyl phosphites. The P—O reactant is preferably represented by liquid P4O6.

Abstract: This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.

Abstract: The invention relates to mixtures composed of monocarboxy-functionalized dialkylphosphinic acids and of further components, which comprise A) from 98 to 100% by weight of monocarboxy-functionalized dialkylphosphinic acids of the formula (I) in which R1, R2, R3, R4, R5, R6, and R7 are identical or different and, independently of one another, are H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and/or phenyl, X and Y are identical or different and, independently of one another, are H, Li, Na, K, or NH4, and B) from 0 to 2% by weight of halogens, where the entirety of the components always amounts to 100% by weight.

Abstract: The invention relates to a method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ether.

Abstract: The invention relates to addition compounds of a) alkylphosphonous acid derivatives of the formula A-P(?O)(OX)—H (I) in which A represents C2-C18-alkyl, C2-C18-alkylene, C6-C18-arylalkyl, C6-C18-arylalkyl, optionally substituted, and X represents H, C1-C18-alkyl, C6-C18-aryl, C6-C18-arylalkyl, C6-C18-alkylaryl, optionally substituted C2-C18-alkylene, Mg, Ca, Al, Sb, Sn, Ge, Ti, Fe, Zr, Zn, Ce, Bi, Sr, Mn, Cu, Ni, Li, Na, K, H and/or a protonated nitrogenous base, and b) diester-forming olefins of formula (II) in which R2, R4 are identical or different from each other and represent CO2H, CO2R5, R6—CO2H, R6—CO2R5 and R1, R3 are identical or different from each other and represent H, R5; or R1, R4 are identical or different from each other and represent CO2H, CO2R5, R6—CO2H, R6—CO2R5 and R2, R3 are identical or different from each other and represent H, R5; or R2, R4 are identical or different from each other and represent —CO—O—CO—, —CO—S—CO—, —CO—NR1—CO—, —CO—PR1—CO— and R1, R3 are identical or different f

Abstract: The invention relates to a process for preparing mono-carboxy-functionalized dialkylphosphinic acids, dialkylphosphinic esters and dialkylphosphinic salts by means of alkylene oxides, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) in the presence of a catalyst A to form an alkylphosphonous acid, its salt or ester (II), b) the resultant alkylphosphonous acid, its salt or ester (II) is reacted with alkylene oxides of the formula (V) in the presence of a catalyst B, to give a mono-functionalized dialkylphosphinic acid derivative (VI), and c) the resultant mono-functionalized dialkylphosphinic acid derivative (VI) is reacted in the presence a catalyst C to give the mono-carboxy-functionalized dialkylphosphinic acid derivative (III), where R1,R2,R3,R4,R5, and R6 are identical or different and independently of one another are inter alia H, C1-C18-alkyl, C6-C18-aryl, C6-C18-aralkyl or C6-C18-alkylaryl, and X and Y are identical or different and independently of one another are H,

Abstract: The invention relates to a method for producing mono-carboxy-functionalized dialkyiphosphinic acids, esters and salts using a vinyl ester of a carboxylic acid.

Abstract: There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic acid, or a pharmaceutically acceptable derivative of such an acid. There are also provided methods of treatment using such inhibitors, acids and derivatives.

Abstract: The invention relates to a method for producing mono-carboxyfunctional zed dialkylphosphinic acids and esters and salts thereof by means of vinylenes/nitriles, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) to yield an alkylphosphonic acid, salt or ester (II) thereof in the presence of a catalyst A, b) the thus obtained alkylphosphonic acid, salt or ester (II) thereof is reacted with acetylenic compounds of formula (V) to yield a mono-functionalized dialkylphosphinic acid derivative (VI) in the presence of a catalyst B, and c) the thus obtained mono-functionalized dialkylphosphinic acid derivative (VI) is reacted with a hydrogen cyanide source to yield a mono-functionalized dialkylphosphinic acid derivative (VII) in the presence of a catalyst C, and d) the thus obtained monofunctionalized dialkylphosphinic acid derivative (VII); is reacted to yield a monocarboxyfunctionalized dialkylphosphinic acid derivative (III) in the presence of a catalyst D, wherein R1, R2, R3, R4, R5

Abstract: The invention relates to a method for producing mono-carboxyfunctionalized dialkylphosphinic acids and esters and salts thereof, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) to yield an alkylphosphonic acid, salt or ester (H) thereof in the presence of a catalyst A, b) the thus obtained alkylphosphonic acid, salt or ester (II) thereof is reacted with compounds of formula (V) to yield mono-functionalized dialkylphosphinic acid derivatives (VI) in the presence of a catalyst B, and c) the thus obtained mono-functionalized dialkylphosphinic acid derivatives (VI) are reacted to yield a mono-carboxyfunctionalized diakylphosphinic acid derivative (III) in the presence of a catalyst C, wherein R1, R2, R3, R4, R5, R6, R7 are the same or different and stand independently of each other, among other things, for H, C1-C18 alkyl, C6-C18 aryl, C6-C18 aralkyl, C6-C18 alkylaryl and X and Y are the same or different and stand independently of each for H, C1-C18 alkyl, C6-C18 aryl, C6-C18 a

Abstract: The invention relates to a method for producing mono-carboxyfunctionalized dialkylphosphinic acids and esters and salts thereof, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) to yield an alkylphosphonic acid, salt or ester (II) thereof in the presence of a catalyst A, b) the alkylphosphonic acid thus obtained, salt or ester (II) thereof is reacted with an ?,?-unsaturated carboxylic acid derivative (V) to yield a mono-carboxyfunctionalized dialkylphosphinic acid derivative (III) in the presence of a catalyst B, wherein R1, R2, R3, R4, R5, R6, R7 are the same or different and stand independently of each other, among other things, for H, C1-C18 alkyl, C6-C18 aryl, C6-C18 aralkyl, C6-C18 alkylaryl, and X and Y are the same or different and stand independently of each other for H, C1-C18 alkyl, C6-C18 aryl, C6-C18 aralkyl, C6-C18 alkylaryl, Mg, Ca, Al, Sb, Sn, Ge, Ti, Fe, Zr, Zn, Ce, Bi, Sr, Mn, Cu, Ni, Li, Na, K and/or a protonized nitrogen base, and the catalyst A is formed b

Abstract: The invention relates to a method for producing mono-carboxyfunctionalized dialkylphosphinic acids and esters and salts thereof, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) to yield an alkylphosphonic acid, salt or ester (II) thereof in the presence of a catalyst A, b) the thus obtained alkyl phosphonic acid, salt, salt or ester (II) thereof is reacted with compounds of formula (V) and/or (VI?) to yield mono-functionalized dialkylphosphinic acid derivatives (VI) and/or (VI?) in the presence of a catalyst B, and c) the thus obtained mono-functionalized dialkylphosphinic acid derivatives (VI) and/or (VI?) are reacted to yield a mono-carboxyfunctionalized dialkylphosphinic acid derivative (III) in the presence of a catalyst C, wherein R1, R2, R3, R4, R5, R6, R7 are the same or different and stand independently of each other, among other things, for H1 C1-C18 alkyl, C6-C18 aryl, C6-C18 aralkyl, C6-C18 alkylaryl, and X and Y are the same or different and stand independently o

Abstract: Provided herein are methods of decreasing a level of kynurenic acid in a cell and of treating a pathophysiological condition in a subject associated with an increase in kynurenic acid in a subject. In these methods the inhibitory action of dicarboxylic acids or derivatives or analogs thereof are effective to inhibit activity of kynurenine aminotransferase II. Also provided is a method of screening for potential inhibitory compounds for kynurenine aminotransferase II. The dicarboxylic acids or derivatives or analogs thereof may have the structural formula, where R1 is H, NH2 or NHCH3, R2 is H or CH3, n is 0 to 14, and X is —COOH, CH2OH, —PO3H2, —SO3H, or —SO3H; or a pharmacologically acceptable salt.

Abstract: The present invention relates to wood-base materials made flame-retardant with halogen-free organic phosphorus compounds, and to compositions and processes for their production and their use.

Abstract: The invention concerns novel phosphonate derivatives, preparation method, use thereof as ligands modulating T ?9?2 lymphocyte activity and pharmaceutical compositions comprising them.

Abstract: There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic acid, or a pharmaceutically acceptable derivative of such an acid. There are also provided methods of treatment using such inhibitors, acids and derivatives.

Abstract: This invention related to a series of new phosphonic acid derivatives having anti-hyperphosphatemia activity. wherein: A is selected from —(CH2)n—, —CO—, —(CH2)n—CO—(CH2)m—, —(CH2)n—CS—(CH2)m— or a branched alkylene group, B ring and C ring are selected from a benzene ring, naphthalene ring, azulene ring or, heterocycle or fused heterocycle compound, D is —(CH2)(n+1)—, —(CH2)—O—(CH2)m—, —(CH2)—S(O)o—(CH2)m—, —CF3 or —(CH2)n—NR10—(CH2)m— wherein a D ring is connected with the carbon atom composing the C ring, E is selected from an oxygen atom or a sulfur atom, P is a phosphine atom, R1˜R7, wherein R1 and R2, R4 and R5 are joined together with neighbored carbon atom to form 5˜7 membered saturated or unsaturated hydrocarbon ring, or 5˜6 membered fused heterocycle, R1, R2 and R3 are not a hydrogen atom if the B ring is a benzene ring and may be the same or different and are substituents, R8 and R9 are may be the same or different and are substituents, R10 is an alkyl group, n and m are 0-10 and o is 0-2.

Abstract: A novel compound (I) represented by the following formula (1) is provided which is suitable for a dental composition and has a polymerizable group, a carboxyl group and a phosphoric acid group. A method for producing a polymerizable amide is provided, which method can make a condensation reaction of a carboxylic acid with an amine to proceed easily and is excellent in safety: wherein R1, R2 and R3 each independently are a hydrogen atom or a hydrocarbon group having 1 to 20 carbon atoms which may have a substituent; (A) and (B) are each any constituent unit; m is an integer of from 1 to 3; n is an integer of from 1 to 3; R4 is an organic group having 1 to 40 carbon atoms which may have a substituent; R5 is a hydrocarbon group having 1 to 20 carbon atoms which may have a substituent, R6 and R7 each independently are a hydrogen atom, a hydrocarbon group having 1 to 20 carbon atoms which may have a substituent, or a metal atom.

Abstract: The invention relates to a composition containing a particulate solid, an organic or aqueous medium, and a compound with a head group derived from phosphorous acid. The invention further relates to novel compounds, and the use of the compound as a dispersant.

Abstract: The invention provides novel compounds comprising a protracting tag linked to therapeutically active compounds.

Abstract: The present invention relates to adhesive compositions having: a phosphate group-containing monomer (a) having a fluorocarbon group represented by Chemical Formula 1; and a solvent (b), where R is a hydrogen atom or a methyl group, n, p and q are natural numbers 2?n?10, p+q?n and p+q+n?13.

Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.

Abstract: An electrostatic-image-developing toner includes a phosphonic acid based sequestering agent.

Abstract: The invention relates to mixtures composed of dialkylphosphinic esters and of further components, which comprise A) from 98 to 100% by weight of monocarboxy-functionalized dialkylphosphinic esters of the formula (I) in which R1, R2, R3, R4, R5, R6, and R7 are identical or different and, independently of one another, are H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and/or phenyl, Y is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, phenyl, 2-hydroxyethyl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, 2-hydroxybutyl, and/or 6-hydroxyhexyl, allyl, and/or glycerol, X is H, Li, Na, K or NH4, or X is defined as for Y, and then X and Y are two identical radicals or two different radicals of the above organic radicals, and B) from 0 to 2% by weight of halogens, where the entirety of the components always amounts to 100% by weight.

Abstract: The invention relates to salts of alkyl esters of carboxyethyl(alkyl)phosphinic acid, where the salts have the formula (I) R1—P(?O)(OX)—CH2—CH2—CO2R2 in which R1 and R2 are identical or different and, independently of one another, are C1-C20-alkyl, C2-C20-alkenyl, C1-C20-alkynyl, and/or C6-C20-aralkyl, and X is an alkali metal, an element of the second main and transition group, an element of the third main and transition group, an element of the fourth main and transition group, an element of the fifth main and transition group, an element of the sixth main group, an element of the seventh transition group, or an element of the eighth transition group, and also to processes for their preparation, and to their use.

Abstract: This invention related to a series of new phosphonic acid derivatives having anti-hyperphosphatemia activity. (I) [wherein: A is selected from —(CH2)n—, —CO—, —(CH2)n—CO—(CH2)m—, —(CH2)n—CS—(CH2)m— or branched alkylene group. B ring and C ring are selected from benzene ring, naphthalene ring, azulene ring or, heterocycle or fused heterocycle. D is —(CH2)(n+1)—, —(CH2)-O—(CH2)m—, —(CH2)—S(O)o—(CH2)m—, —CF3 or —(CH2)n—NR10—(CH2)m— (wherein: D ring is connected with the carbon atom composing C ring.) E is selected from oxygen atom or sulfur atom. P is phosphine atom. R1˜R7 (wherein R1 and R2, R4 and R5 are joined together with neighbored carbon atom to form 5˜7 membered saturated or unsaturated hydrocarbon ring, or 5˜6 membered fused heterocycle. R1, R2 and R3 are not hydrogen atom if B ring is benzene ring.) may be the same or different and are substituents. R8 and R9 are may be the same or different and are substituents. R10 is alkyl group. n and m are 0-10. o is 0-2.

Abstract: An improved process for the manufacture of formylphosphonic acid derivatives is reported. An aminomethylphosphonic acid substrate is contacted with a reagent selected from the group consisting of water, an alcohol, a phenol compound, and mixtures thereof and an oxidizing gas in the presence of a catalyst to form a reaction product mixture containing a formylphosphonic acid derivative and the conditions under which said contacting is carried out are controlled so that no more than 50% of the formylphosphonic acid derivative formed in the reaction product mixture is consumed by reaction with the reagent.

Abstract: The invention relates to mixtures composed of monocarboxy-functionalized dialkylphosphinic acids and of further components, which comprise A) from 98 to 100% by weight of monocarboxy-functionalized dialkylphosphinic acids of the formula (I) in which R1, R2, R3, R4, R5, R6, and R7 are identical or different and, independently of one another, are H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and/or phenyl, X and Y are identical or different and, independently of one another, are H, Li, Na, K, or NH4, and B) from 0 to 2% by weight of halogens, where the entirety of the components always amounts to 100% by weight.

Abstract: The invention relates to a process for preparing N-phosphono-methylglycine by reacting a hexahydrotriazine compound with a triacyl phosphite in an organic solvent, hydrolyzing the resulting phosphono compound after prior extraction into an aqueous phase and separation from the organic phase. The process avoids decomposition of the organic solvent during hydrolysis.

Abstract: An improved process for the manufacture of formylphosphonic acid derivatives is reported. An aminomethylphosphonic acid substrate is contacted with a reagent selected from the group consisting of water, an alcohol, a phenol compound, and mixtures thereof and an oxidizing gas in the presence of a catalyst to form a reaction product mixture containing a formylphosphonic acid derivative and the conditions under which said contacting is carried out are controlled so that no more than 50% of the formylphosphonic acid derivative formed in the reaction product mixture is consumed by reaction with the reagent.

Abstract: A newly discovered antineoplastic compound denominated “phenstatin” is herein described as are synthetic methods for producing phenstatin and the active prodrug thereof. Phenstatin was converted to the sodium phosphate prodrug (3d) by a dibenzylphosphite phosphorylation and subsequent hydrogenolysis sequence 3b?3c?3d. Phenstatin (3b) was found to be a potent inhibitor of tubulin polymerization and the binding of colchicine to tubulin comparable to combretastatin A-4 (1b).

Abstract: Compounds useful as surface coating agents, including compounds of the formula: wherein X1 comprises a first photoreactive species; X2 comprises a second photoreactive species; Y comprises a nonpolymeric core molecule comprising an aromatic group; and Z comprises at least one charged group. The Y core can include an aromatic group such as a benzene radical, the charged groups Z can be independently selected from the organic acids that include sulfonic acid, carboxylic acid, and phosphoric acid, and the photoreactive species of X1 and X2 can independently be aryl ketones, such as those selected from the group acetophenone, benzophenone, anthraquinone, anthrone, and anthrone-like heterocycles, and their substituted derivatives.

Abstract: Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

Abstract: The present invention concerns compounds of formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, 1

Abstract: Disclosed are 4-(difluoromethylene)phosphonate cinnamic acid derivatives as a molecular scaffold for the preparation of protein tyrosine phosphatase inhibitors. The invention also relates to a process for the combinatorial preparation of protein tyrosine phospatase inhibitors possessing a 4-(difluoromethylene)phosphonate cinnamic acid/ester molecular scaffold.

Abstract: An improved process for the manufacture of formylphosphonic acid derivatives is reported. An aminomethylphosphonic acid substrate is contacted with a reagent selected from the group consisting of water, an alcohol, a phenol compound, and mixtures thereof and an oxidizing gas in the presence of a catalyst to form a reaction product mixture containing a formylphosphonic acid derivative and the conditions under which said contacting is carried out are controlled so that no more than 50% of the formylphosphonic acid derivative formed in the reaction product mixture is consumed by reaction with the reagent.

Abstract: There is disclosed an advantageous mixed acid anhydride production method of formula (1): R1C(O)OY(O)n(R2)p  (1) wherein R1, R2 and Y denote the same as defined below, n and p denote an integer of 1 or 2, which is characterized by adding a carboxylic acid of formula (2); R1COOH  (2) wherein R1 denotes a hydrogen atom, an optionally substituted alkyl group or the like, an organic base to a solution of a carboxylic acid activating agent of formula (3); (R2)pY(O)nX  (3) wherein R2 denotes an optionally substituted aliphatic hydrocarbyl group or the like, Y denotes a carbon atom, a phosphorus atom, or a sulfur atom, and X denotes a chlorine atom or the like.